In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
The closing price of Celldex Therapeutics Inc (NASDAQ: CLDX) was $16.85 for the day, down -7.16% from the previous closing price of $18.15. In other words, the price has decreased by -$7.16 from its previous closing price. On the day, 1.11 million shares were traded. CLDX stock price reached its highest trading level at $18.03 during the session, while it also had its lowest trading level at $16.745.
Ratios:
Our analysis of CLDX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 18.91 and its Current Ratio is at 18.91. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Morgan Stanley on March 20, 2025, initiated with a Overweight rating and assigned the stock a target price of $46.
On February 13, 2025, UBS started tracking the stock assigning a Buy rating and target price of $44.
On October 07, 2024, Citigroup started tracking the stock assigning a Buy rating and target price of $70.Citigroup initiated its Buy rating on October 07, 2024, with a $70 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Nov 11 ’24 when Marucci Anthony S bought 11,500 shares for $26.82 per share. The transaction valued at 308,430 led to the insider holds 40,284 shares of the business.
Martin Samuel Bates sold 17,172 shares of CLDX for $608,315 on Jun 14 ’24. The SVP AND CFO now owns 28,125 shares after completing the transaction at $35.42 per share. On Jun 14 ’24, another insider, Crowley Elizabeth, who serves as the SR. VP & CPDO of the company, sold 30,000 shares for $34.87 each. As a result, the insider received 1,045,962 and left with 9,074 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLDX now has a Market Capitalization of 1118567040 and an Enterprise Value of 397099200. For the stock, the TTM Price-to-Sale (P/S) ratio is 159.34 while its Price-to-Book (P/B) ratio in mrq is 1.50. Its current Enterprise Value per Revenue stands at 56.567 whereas that against EBITDA is -2.069.
Stock Price History:
The Beta on a monthly basis for CLDX is 1.59, which has changed by -0.58240396 over the last 52 weeks, in comparison to a change of 0.08089435 over the same period for the S&P500. Over the past 52 weeks, CLDX has reached a high of $47.00, while it has fallen to a 52-week low of $17.63. The 50-Day Moving Average of the stock is -22.23%, while the 200-Day Moving Average is calculated to be -43.17%.
Shares Statistics:
CLDX traded an average of 873.77K shares per day over the past three months and 825890 shares per day over the past ten days. A total of 66.37M shares are outstanding, with a floating share count of 64.70M. Insiders hold about 2.54% of the company’s shares, while institutions hold 109.76% stake in the company. Shares short for CLDX as of 1741910400 were 9151823 with a Short Ratio of 10.47, compared to 1739491200 on 9192670. Therefore, it implies a Short% of Shares Outstanding of 9151823 and a Short% of Float of 15.939999999999998.
